1. Home
  2. GTY vs NUVB Comparison

GTY vs NUVB Comparison

Compare GTY & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GTY

Getty Realty Corporation

HOLD

Current Price

$36.09

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Nuvation Bio Inc.

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$5.78

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTY
NUVB
Founded
1955
2018
Country
United States
United States
Employees
N/A
307
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
GTY
NUVB
Price
$36.09
$5.78
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$32.60
$11.38
AVG Volume (30 Days)
533.0K
9.1M
Earning Date
04-22-2026
05-04-2026
Dividend Yield
5.92%
N/A
EPS Growth
8.00
N/A
EPS
0.43
N/A
Revenue
$221,727,000.00
N/A
Revenue This Year
$9.39
$203.82
Revenue Next Year
$7.83
$58.18
P/E Ratio
$83.93
N/A
Revenue Growth
9.02
N/A
52 Week Low
$25.39
$2.18
52 Week High
$36.12
$9.75

Technical Indicators

Market Signals
Indicator
GTY
NUVB
Relative Strength Index (RSI) 73.33 54.31
Support Level $32.41 $5.26
Resistance Level N/A $6.37
Average True Range (ATR) 0.58 0.36
MACD 0.18 -0.04
Stochastic Oscillator 87.54 47.09

Price Performance

Historical Comparison
GTY
NUVB

About GTY Getty Realty Corporation

Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: